AT&T's $177 million settlement is for data breaches in 2019 and 2024. Claim up to $5,000 (first breach) and $2,500 (Snowflake hack), or both. File claim by Dec. 18, 2025, either online or by mail. If ...
GATE DA Syllabus 2026: The candidates who are preparing for the GATE 2026 Data Science & Artificial Intelligence (DA) exam must go through the GATE Data Science & Artificial Intelligence syllabus. IIT ...
BAAR, Switzerland - Novocure (NASDAQ:NVCR), a $1.47 billion medical technology company whose shares have declined over 55% year-to-date, will present research data on its Tumor Treating Fields ...
DUBLIN and CHICAGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections ...
BOSTON/UTRECHT - Oncology company Merus N.V. (NASDAQ:MRUS), currently valued at $7.16 billion and showing impressive momentum with a 125% gain over the past six months, announced Monday that it will ...
New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie's growing ADC portfolio designed to target ...
I don’t use Microsoft Excel all that often, so it remains a bit of a mystery to me. I can enter text and create graphs and that’s basically it. That’s why I’ve set myself a goal to learn one new Excel ...
Connecting the dots: US economic growth in 2025 is being driven by an unprecedented surge in AI-related infrastructure spending – an inversion of the forces that have long powered expansion. The boom ...
ZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. ABIVAX Société Anonyme is one of them. ABIVAX Société Anonyme (NASDAQ:ABVX) is a clinical-stage biotechnology ...
REDMOND, Wash., Sept. 24, 2025 /PRNewswire/ -- SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation of data on iza-bren (izalontamab brengitecan) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback